Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Work In Process (2023 - 2025)

Tarsus Pharmaceuticals (TARS) has 3 years of Work In Process data on record, last reported at $1.4 million in Q4 2025.

  • For Q4 2025, Work In Process rose 129.64% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $1.4 million, up 129.64%, while the annual FY2025 figure was $1.4 million, 129.64% up from the prior year.
  • Work In Process reached $1.4 million in Q4 2025 per TARS's latest filing, up from $1.0 million in the prior quarter.
  • Across five years, Work In Process topped out at $1.6 million in Q3 2024 and bottomed at $392000.0 in Q4 2023.
  • Average Work In Process over 3 years is $1.0 million, with a median of $1.0 million recorded in 2025.
  • The widest YoY moves for Work In Process: up 129.64% in 2025, down 37.12% in 2025.
  • A 3-year view of Work In Process shows it stood at $392000.0 in 2023, then soared by 56.63% to $614000.0 in 2024, then skyrocketed by 129.64% to $1.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Work In Process were $1.4 million in Q4 2025, $1.0 million in Q3 2025, and $1.6 million in Q2 2025.